Loading institutional data...
Loading institutional data...
Held by 2,196 of 5,944 reporting institutions (100th percentile) — extremely crowded.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $280.13 today, the market must believe free cash flow compounds 14.4%/yr for a decade (off $3.6B normalized FCF).
The market's 14.4% is more optimistic than its 9-yr track record.
2-stage DCF · 0.38B shares · net debt $11.8B
mean 21.9% · volatility σ 51% · implied rate exceeded in 4/9 yrs
Central path = implied 14.4%/yr growth; shaded band = ±1σ (51%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Comfortably covers interest; leverage falling year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
The dividend is comfortably covered — only 30% of free cash flow, leaving room to grow it and fund buybacks. Last year: $1.3B dividends + $0 buybacks = $1.3B returned on $4.3B FCF.
9 consecutive years of dividend increases · 9%/yr.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Modest payoff on reinvested capital. Current ROIC on all capital: 8%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $4.0B covers the $1.0B due within a year 4.0× over. Scheduled principal only (excludes interest & revolver draws). As of 2025-12-31 (10-K).
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~3.8% on $15.9B of debt.
Cash of $4.0B fully covers short-term debt of $1.0B.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-09-17
How a revenue dollar becomes profit — FY2025
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $25.12B 100.0% | $22.59B 100.0% | $20.50B 100.0% | $18.45B 100.0% | $17.11B 100.0% | $14.35B 100.0% | $14.88B 100.0% | $13.60B 100.0% | $12.44B 100.0% | $11.32B 100.0% |
| Cost of Revenue | $9.05B 36.0% | $8.15B 36.1% | $7.44B 36.3% | $6.87B 37.2% | $6.14B 35.9% | $5.29B 36.9% | $5.19B 34.9% | $4.66B 34.3% | $4.26B 34.3% | $3.82B 33.7% |
| Cost of Products | — | — | — | — | — | — | — | — | $4.27B 34.3% | $3.83B 33.8% |
| Gross Profit | $16.07B 64.0% | $14.44B 63.9% | $13.06B 63.7% | $11.58B 62.8% | $10.97B 64.1% | $9.06B 63.1% | $9.70B 65.1% | $8.94B 65.7% | $8.18B 65.7% | $7.50B 66.3% |
| Research & Development | $1.62B 6.5% | $1.47B 6.5% | $1.39B 6.8% | $1.45B 7.9% | $1.24B 7.2% | $984.0M 6.9% | $971.0M 6.5% | $862.0M 6.3% | $787.0M 6.3% | $715.0M 6.3% |
| Selling, General & Admin | $8.65B 34.4% | $7.68B 34.0% | $7.11B 34.7% | $6.39B 34.6% | $6.43B 37.6% | $5.36B 37.4% | $5.36B 36.0% | $5.10B 37.5% | $4.55B 36.6% | $4.14B 36.5% |
| Total Operating Expenses | $11.18B 44.5% | $10.75B 47.6% | $9.17B 44.7% | $8.74B 47.4% | $8.38B 49.0% | $6.83B 47.6% | $6.98B 46.9% | $6.40B 47.1% | $5.88B 47.3% | $5.33B 47.1% |
| Operating Income | $4.89B 19.5% | $3.69B 16.3% | $3.89B 19.0% | $2.84B 15.4% | $2.58B 15.1% | $2.22B 15.5% | $2.71B 18.2% | $2.54B 18.7% | $2.30B 18.5% | $2.17B 19.2% |
| Interest Expense | $607.0M 2.4% | $409.0M 1.8% | $363.0M 1.8% | $337.0M 1.8% | $337.0M 2.0% | $315.0M 2.2% | $287.0M 1.9% | $264.0M 1.9% | $247.0M 2.0% | $228.0M 2.0% |
| Other Income (Expense), net | $232.0M 0.9% | $212.0M 0.9% | $148.0M 0.7% | -$158.0M -0.9% | -$303.0M -1.8% | -$269.0M -1.9% | -$151.0M -1.0% | -$181.0M -1.3% | -$234.0M -1.9% | -$254.0M -2.2% |
| Pretax Income | $4.51B 18.0% | $3.49B 15.5% | $3.67B 17.9% | $2.68B 14.5% | $2.28B 13.3% | $1.95B 13.6% | $2.56B 17.2% | $2.36B 17.3% | $2.06B 16.6% | $1.92B 17.0% |
| Income Tax Expense | $1.27B 5.0% | $499.0M 2.2% | $508.0M 2.5% | $325.0M 1.8% | $287.0M 1.7% | $355.0M 2.5% | $479.0M 3.2% | -$1.20B -8.8% | $1.04B 8.4% | $274.0M 2.4% |
| Net Income | $3.25B 12.9% | $2.99B 13.2% | $3.17B 15.4% | $2.36B 12.8% | $1.99B 11.7% | $1.60B 11.1% | $2.08B 14.0% | $3.55B 26.1% | $1.02B 8.2% | $1.65B 14.5% |
| Per Share | ||||||||||
| EPS (Basic) | $8.49 | $7.86 | $8.34 | $6.23 | $5.29 | $4.26 | $5.57 | $9.50 | $2.73 | $4.40 |
| EPS (Diluted) | $8.40 | $7.76 | $8.25 | $6.17 | $5.21 | $4.20 | $5.48 | $9.34 | $2.68 | $4.35 |
| Weighted Avg Shares (Basic) | 382.2M | 381.0M | 379.6M | 378.2M | 377.0M | 375.5M | 374.0M | 374.1M | 374.0M | 374.1M |
| Weighted Avg Shares (Diluted) | 386.5M | 385.6M | 383.7M | 382.2M | 382.3M | 380.3M | 379.9M | 380.3M | 380.1M | 378.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Top 40 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-09-17
Nothing notable to watch.
No material risks flagged.
Where each multiple sits in its own 14-yr range · 45th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 2.9× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 34.3 | 34.9 | 36.9 | 35.9 | 37.2 | 36.3 | 36.1 | 36.0 |
| Gross Profit | 65.7 | 65.1 | 63.1 | 64.1 | 62.8 | 63.7 | 63.9 | 64.0 |
| R&D | 6.3 | 6.5 | 6.9 | 7.2 | 7.9 | 6.8 | 6.5 | 6.5 |
| SG&A | 37.5 | 36.0 | 37.4 | 37.6 | 34.6 | 34.7 | 34.0 | 34.4 |
| Operating Income | 18.7 | 18.2 | 15.5 | 15.1 | 15.4 | 19.0 | 16.3 | 19.5 |
| Income Tax | -8.8 | 3.2 | 2.5 | 1.7 | 1.8 | 2.5 | 2.2 | 5.0 |
| Net Income | 26.1 | 14.0 | 11.1 | 11.7 | 12.8 | 15.4 | 13.2 | 12.9 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on SYK: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
Ranked against 1085 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BCAX | $1.20T | — | — | — | — | — | — | -34.4% | -34.4% | — | 143 |
| LLY | $1.02T | 49.6× | — | 15.7× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $916.2B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $643.4B | 24.2× | — | 6.8× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $464.4B | 111.2× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| MRK | $362.6B | 19.9× | — | 5.6× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| UNH | $340.0B | 28.4× | 19.7× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| AZN | $252.6B | — | — | — | — | — | — | — | — | — | 1,248 |
| TMO | $244.5B | 36.5× | 31.5× | 5.5× | 3.9% | — | 15.0% | 12.6% | 7.0% | 4.9× | 2,481 |
| AMGN | $202.8B | 26.4× | 17.4× | 5.5× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.8× | 3,014 |
| GILD | $183.3B | 21.8× | 20.0× | 6.2× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| ABT | $178.2B | 27.5× | 19.3× | 4.0× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 1.4× | 2,964 |
| PFE | $156.1B | 20.2× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $147.3B | 41.3× | 30.5× | 6.0× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $135.8B | 48.6× | 37.3× | 13.5× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| VRTX | $130.4B | 33.5× | 28.6× | 10.9× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| BMY | $129.4B | 18.4× | — | 2.7× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,431 |
| MDT | $118.5B | 24.8× | 12.6× | 3.3× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| LGVN | $117.4B | — | — | 97924.4× | -49.9% | 67.0% | -1894% | -400% | -400% | — | 31 |
| CVS | $116.6B | 66.0× | 11.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| SYK | $108.8B | 33.9× | 18.7× | 4.3× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| MCK | $103.4B | 23.1× | 16.3× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| HCA | $96.7B | 15.2× | — | 1.3× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $91.1B | 16.4× | 15.4× | 0.5× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| REGN | $81.0B | 18.7× | 19.4× | 5.7× | 1.0% | — | 31.4% | 14.4% | 13.6% | 0.5× | 1,336 |
Peers = companies sharing SYK's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.